A shortage that cannot clear the usual way
More than 100,000 people sit on the American transplant waiting list, over 92,000 of them waiting for a kidney. The gap between need and supply is not abstract. In 2021 the transplant network recorded 5,758 people removed from the list because they had died, and another 5,371 removed because they had become too sick to transplant. In an ordinary market a shortage that severe would be met by a rising price, which would pull more supply toward the need. For kidneys, that path is closed. The National Organ Transplant Act of 1984 makes it a federal crime to buy or sell a human organ in the United States, and most of the world takes the same view.
Why the price is forbidden
The ban is not an oversight, and it deserves to be stated at its strongest. A price for organs would fall hardest on the poor, who would be the ones selling, and it risks turning the body into collateral and consent into something bought. Those are serious objections, widely held, and this piece takes no view on whether they should win. The point here is narrower and follows from the rest of the series: forbidding the price does not remove the allocation problem. It only means the problem must be solved some other way, because the kidneys still have to be matched to the people who need them.
The market built without money
The other way is one of the quiet triumphs of modern economics. Many willing donors cannot give to the person they came to help, because blood or tissue types do not match. Alvin Roth, who won the Nobel Prize in economics in 2012, helped design kidney paired-donation exchanges that solve exactly this. Two incompatible pairs are matched so that each donor gives to the other pair's patient; longer chains link many pairs at once, often begun by a single altruistic donor and rippling through a dozen transplants. It is a market in the deepest sense, matching supply to demand and clearing a shortage, and it runs entirely without a price. The same matching machinery, built on the stable-matching theory Roth extended, now assigns doctors to hospitals and children to schools.
The evidence the ban leaves on the table
Sitting awkwardly beside all this is one country. Iran has run a legal, government-regulated market in which kidney donors are paid since 1988, and by 1999 it had effectively eliminated its kidney transplant waiting list. That fact is not a recommendation, and the Iranian system carries its own well-documented problems of coercion and hardship among the poor donors it draws on. But it is evidence, and honesty requires letting it stand: where the price is allowed, the shortage that kills thousands elsewhere does not exist in the same way.
The point
This is the inversion of everything else in the series. Usually the absence of a market means the thing cannot be standardised or cleared, that the underlying will not support a price. Here the market could plainly form, and has been forbidden on purpose, for reasons many people find compelling. The lesson is what that choice actually costs. A price is one mechanism for moving a scarce thing to where it is needed most, and when a society bans the price, it does not escape the problem; it takes on the duty of building something else to do the price's work, and of living with whatever gap that something leaves.
For kidneys, the something is a matching market of real beauty that has saved thousands of lives, and a waiting list that is still measured in the tens of thousands. Both of those are consequences of the same decision. The absence of a price is not a market failure here. It is a moral choice, and its cost is written, plainly and terribly, in the length of the list.
Levanter Markets publishes for education. Nothing here is financial advice.